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Abstract
Background: Recent evidence suggests that there may be a bidirectional, physiological link between
hypogonadism and metabolic syndrome (MetS), and testosterone replacement therapy (TRT) has been shown to
improve some symptoms of MetS in small patient populations. We examined the effect of 12 months of TRT on
MetS components in a large cohort of hypogonadal men.
Methods: Data were obtained from TRiUS (Testim
® Registry in the United States), a 12-month, multicenter,
prospective observational registry (N = 849) of hypogonadal men prescribed Testim 1% testosterone gel (5-10 g/
day). Data analyzed included age, total testosterone (TT), free testosterone (FT), sex hormone-binding globulin
(SHBG), and MetS components: waist circumference, blood pressure, fasting blood glucose, plasma triglycerides,
and HDL cholesterol.
Results: Of evaluable patients (581/849) at baseline, 37% were MetS+ (n = 213) and 63% were MetS- (n = 368).
MetS+ patients had significantly lower TT (p < 0.0001) and SHBG (p = 0.01) levels. Patients with the lowest quartile
TT levels (<206 ng/dL [<7.1 nmol/L]) had a significantly increased risk of MetS+ classification vs those with highest
quartile TT levels (≥331 ng/dL [≥11.5 nmol/L]) (odds ratio 2.66; 95% CI, 1.60 to 4.43). After 12 months of TRT, TT
levels significantly increased in all patients (p < 0.005). Despite having similar TT levels after TRT, only MetS+
patients demonstrated significant decreases in waist circumference, fasting blood glucose levels, and blood
pressure; lowest TT quartile patients demonstrated significant decreases in waist circumference and fasting blood
glucose. Neither HDL cholesterol nor triglyceride levels changed significantly in either patient population.
Conclusion: Hypogonadal MetS+ patients were more likely than their MetS- counterparts to have lower baseline
TT levels and present with more comorbid conditions. MetS+ patients and those in the lowest TT quartile showed
improvement in some metabolic syndrome components after 12 months of TRT. While it is currently unclear if
further cardiometabolic benefit can be seen with longer TRT use in this population, testing for low testosterone
may be warranted in MetS+ men with hypogonadal symptoms.
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Hypogonadism is commonly found in middle-aged and
older men [1]; symptoms may include decreased muscle
mass and strength, increased abdominal fat, decreased
sexual interest and function, depressed mood, and fatigue
[2]. While the prevalence and symptoms of hypogonad-
ism are associated with aging [3], the presence of certain
comorbidities and cardiovascular risk factors are also
associated with low testosterone levels [1], including the
components of metabolic syndrome (MetS) [4]. Accord-
ing to the ATP III and AHA/NHLBI guidelines [5,6] the
components of MetS include: insulin resistance,
increased waist circumference, high triglycerides, low
high-density lipoprotein (HDL) cholesterol, and increased
blood pressure (BP).
The worldwide prevalence of MetS has dramatically
increased over the past 20 years [7]. Evidence suggests
that there may be a bidirectional, physiological link
between hypogonadism and MetS [4]. Reduced testoster-
one levels can lead to muscle loss and weight gain, and is
a significant predictor of MetS and type 2 diabetes in men
[8-10]. Hyperinsulinemia and obesity may inhibit testicular
testosterone production [10]. Testosterone replacement
therapy (TRT) in hypogonadal men improves lean body
mass and reduces fat mass [11], and may improve some
symptoms of MetS and type 2 diabetes [12-14]. However,
there have been four placebo-controlled, randomized trials
[15-18] and a meta-analysis [19] published to date that
have effectively evaluated the potential of TRT for meta-
bolic symptom improvement.
There is a lack of studies of general populations of hypo-
gonadal men that examined the effect of TRT on meta-
bolic symptoms. We used data collected through the
Testim
® Registry in the United States (TRiUS) to investi-
gate the prevalence of MetS and associated comorbidities
in a large community-based population of men with hypo-
gonadism and examined the effects of long-term (12-
month) TRT on MetS components.
TRiUS was established as a prospective observational
study (ie, patient registry) of hypogonadal men (N = 849)
treated with testosterone gel (Testim 1%). The objective of
this analysis was to determine whether restoring testoster-
one levels in men with hypogonadism in typical clinical
settings could improve components of MetS.
Methods
Data were part of the TRiUS patient registry of hypogo-
nadal men, whose methodology and baseline demo-
graphics have been described previously [20]. As with
other patient registry or observational study designs, the
TRiUS methodology reflected typical clinical practice:
there was no placebo control or control patient popula-
tion and data collection was limited to the patients who
were available at each time point. Inclusion criteria for
the registry included hypogonadal males who provided
informed consent and were naïve to Testim therapy at
enrollment, though not necessarily naïve to other forms
o fT R T .E x c l u s i o nc r i t e r i af o rt h er e g i s t r yi n c l u d e d
patients who demonstrated hypersensitivity to any ingre-
dients in the testosterone gel (including testosterone),
had breast cancer, or had known or suspected prostate
cancer. All study sites had local or central Institutional
Review Board (IRB) approval, and research was carried
out in compliance with the Declaration of Helsinki as
currently amended.
Testosterone gel dosing was prescribed at the physi-
cian’s discretion and could be titrated up or down at any
time during the 12-month study period in order to
achieve the desired steady-state total testosterone (TT)
level. Follow-up examinations were suggested at approxi-
mately 1, 3, 6, and 12 months after the initiation of ther-
apy, although actual follow-up visits were also at the
discretion of the physician. Visits occurring within a spe-
cified time window of a suggested time point (±14 days
for month 1, ±30 days for months 3 and 6, and visits at
day 330 or later for month 12) were grouped within that
time point. If a patient had multiple visits within the spe-
cified time window before or after a time point, the visit
closest to the designated time point was used.
Suggested assessments at visits included, but were not
limited to: testosterone levels (total, free, and bioavail-
able), PSA, anthropometric measures, vital signs, choles-
terol panel, hematology, and fasting glucose measures,
and were measured according to the physician’su s u a l
practice, including the measurement of free testosterone.
Patient self-report of comorbid conditions and diseases
such as diabetes, hypertension, dyslipidemia, and sleep
apnea were recorded, as well as use of antidepressants,
opioids, and phosphodiesterase type 5 (PDE5) inhibitors.
Assessment measures and medical history from elec-
tronic clinical response forms were used to characterize
men as positive (MetS+) or negative (MetS-) for MetS.
ATP III and AHA/NHLBI criteria [5,6] required 3 of 5
of the following characteristics for MetS+ classification:
central obesity (waist circumference >102 cm [40
inches]), high BP (systolic BP ≥130 mmHg or diastolic
BP ≥85 mmHg or medical history of hypertension), high
fasting blood glucose (>100 mg/dL [>5.6 mmol/L]),
hyperlipidemia (triglycerides >150 mg/dL [>1.7 mmol/
L]), and low HDL cholesterol (<40 mg/dL [<1.0 mmol/
L]).
If 3 of 5 criteria could not give a definitive MetS+ or
MetS- classification, then the patient was excluded from
analysis. For example, if a patient was positive for 2 of 4
criteria but data on the fifth criteria were missing, then
no classification could be made and the patient was
excluded from further analyses (ie, was not included in
either group). Data for all 5 criteria were not necessary
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classification.
Statistical analysis
Comparisons between subjects classified as MetS+ vs
MetS- were performed using Fisher’s exact test for catego-
rical variables, and t-tests of means for numerically contin-
uous variables. Baseline correlations were examined using
the Pearson (r) first-order partial correlation coefficient
adjusting for age. The continuous effect of age on testos-
terone levels at baseline was examined using an analysis of
covariance (ANCOVA). Odds ratios were calculated using
logistic regression models. All changes from baseline
values were examined using repeated measures analysis of
variance (ANOVA) based on a mixed model with two
fixed effects: Post-baseline visit (months 3, 6, and 12) and
either MetS status (+ or -) or baseline TT quartile. P-
values ≤0.05 were considered statistically significant and
no Bonferroni corrections were made for multiple com-
parisons. All analyses were performed using an a priori
analysis plan with SAS
® (SAS Institute, Cary NC, version
9.1).
Results
MetS criteria were examined for the 849 patients enrolled
in the TRiUS registry. At baseline, 32% (268/849) did not
have enough data to determine MetS status and were
excluded from this analysis. Of those evaluated (n = 581),
213 (37%) patients were classified as with MetS (MetS+),
and 368 (63%) patients were classified as without (MetS-).
The two cohorts were statistically different (p = 0.04) in
mean age (Table 1).
Of the 581 evaluable patients at baseline, a variable
number were available for data collection at 3, 6, and 12
months of TRT: 160 patients at 3 months, 233 patients at
6 months, and 218 patients at 12 months. The percentages
of MetS+ patients were as follows: 41.3% (66/160) at
3 months, 36.9% (86/233) at 6 months, and 40.4% (88/
218) at 12 months. The remaining percentages were
MetS- patients.
Analysis at baseline
Comparison between MetS+ and MetS- patients at baseline
As expected, MetS+ and MetS- cohorts showed statisti-
cally significant differences in MetS components and
related measures (Table 1) and in the prevalence of cardio-
vascular and metabolic comorbid conditions (Figure 1).
Odds ratios of MetS status by TT and SHBG levels at
baseline
Because MetS+ patients had significantly lower TT and
SHBG levels (Figure 2), we examined if either of these
levels were associated with an increased chance of being
MetS+. To study the effect of TT levels, those patients
with baseline TT measures (n = 528) were divided into
quartiles based upon the distribution of testosterone levels
among this population: <206, 206-256, 257-330, and ≥331
ng/dL [<7.1, 7.1-8.9, 8.9-11.5, and ≥11.5 nmol/L]. The per-
centage of MetS+ patients in each quartile were as follows:
Quartile 1 (<206 ng/dL [<7.1 nmol/L]) = 50.4% (66/131);
Quartile 2 (206-256 ng/dL [7.1-8.9 nmol/L]) = 39.1% (50/
128); Quartile 3 (257-330 ng/dL [8.9-11.5 nmol/L]) =
37.8% (51/135); and Quartile 4 (≥331 ng/dL [≥11.5 nmol/
L]) = 27.6% (37/134). As expected, the highest percentage
of MetS+ patients was in the lowest TT quartile.
Using the highest quartile (≥331 ng/dL [≥11.5 nmol/L])
as a reference, the odds ratios for MetS+ status among TT
level quartiles were as follows: Quartile 1 (<206 ng/dL
[<7.1 nmol/L]) = 2.66 (95% CI, 1.60 to 4.43); Quartile 2
(206-256 ng/dL [7.1-8.9 nmol/L]) = 1.68 (95% CI, 1.00 to
2.82); and Quartile 3 (257-330 ng/dL [8.9-11.5 nmol/L]) =
1.59 (95% CI, 0.95 to 2.66). The odds of being classified as
MetS+ were significantly greater (p = 0.002) for patients in
Quartile 1 (TT <206 ng/dL [<7.1 nmol/L]) than those in
Quartile 3 (TT 257-330 ng/dL [8.9-11.5 nmol/L]) in a
hypogonadal population.
SHBG levels (n = 104) were divided by the median value
(≤23 and >23 nmol/L). The percentages of MetS+ patients
w e r e3 9 . 1 %i nt h el o wS H B G( ≤23 nmol/L) group and
29.3% in the normal SHBG (>23 nmol/L) group. The odds
ratio of being classified as MetS+ for the low SHBG group
vs the normal SHBG group was 1.55 (95% CI, 0.68 to 3.52)
and was not significant (p = 0.3). Thus, TT levels seemed
to be a better indicator of metabolic syndrome status than
SHBG levels in our study.
Correlations of baseline TT levels with anthropometric and
blood pressure measures
These odds ratios suggested that TT levels may correlate
to the components of MetS. We found that TT levels sig-
nificantly and inversely correlated (p < 0.005) with all
anthropometric and hemodynamic measures (Table 2),
even after partialing out the effects of age. Free testoster-
one, bioavailable testosterone, and SHBG levels did not
significantly correlate with MetS components, with the
exception of free testosterone and diastolic blood pressure
(p = 0.04).
Analysis after testosterone replacement therapy
We analyzed data from the 3-, 6-, and 12-month follow-up
records of the 581 evaluable MetS+ and MetS- registry
patients. Prescription compliance (calculated for each
patient as total number of compliant days divided by the
total number of days prescribed TRT) was based on
patient diary information and could be determined in 55%
(321/581) of the population; compliance rates were com-
parable between MetS+ and MetS- patients (90.7 ± 1.5%,
n = 107 vs 93.6 ± 0.9%, n = 189, respectively; p = 0.1).
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Characteristic Overall
(N = 849)
MetS+
(n = 213)
MetS-
(n = 368)
p-Value
(+ vs -)
Mean ± SD
Mean age, yrs (range) 52.1 ± 12.3
(20-85)
(n = 845)
53.0 ± 11.3
(21-83)
(n = 212)
50.9 ± 12.2
(24-85)
(n = 367)
0.04
Hip circumference, cm [inches] 106.4 ± 14.7 [41.9 ± 5.8]
(n = 836)
114.0 ± 15.0 [44.9 ± 5.9]
(n = 212)
100.1 ± 12.2 [39.4 ± 4.8]
(n = 364)
<0.0001
BMI, kg/m
2 31.4 ± 6.9
(n = 846)
34.6 ± 6.6
(n = 213)
28.7 ± 6.4
(n = 368)
<0.0001
Waist circumference, cm [inches] 103.9 ± 16.5 [40.9 ± 6.5]
(n = 835)
114.3 ± 16.0 [45.0 ± 6.3]
(n = 211)
95.5 ± 13.7 [37.6 ± 5.4]
(n = 363)
<0.0001
Fasting blood glucose, mg/dL [mmol/L] 106.4 ± 36.6
[5.9 ± 2.0]
(n = 455)
118.3 ± 40.0
[6.6 ± 2.2]
(n = 189)
96.6 ± 31.2
[5.4 ± 1.7]
(n = 244)
<0.0001
Systolic BP, mmHg 129.2 ± 15.3
(n = 845)
134.3 ± 15.8
(n = 213)
122.8 ± 12.9
(n = 364)
<0.0001
Diastolic BP, mmHg 79.5 ± 9.5
(n = 845)
82.5 ± 9.6
(n = 213)
76.1 ± 8.3
(n = 365)
<0.0001
HDL cholesterol, mg/dL
[mmol/L]
43.3 ± 12.6
[1.1 ± 0.3]
(n = 468)
38.1 ± 9.6
[1.0 ± 0.2]
(n = 203)
47.8 ± 12.8
[1.3 ± 0.3]
(n = 241)
<0.0001
LDL cholesterol, mg/dL
[mmol/L]
104.3 ± 37.9
[2.7 ± 1.0]
(n = 456)
99.7 ± 36.1
[2.6 ± 0.9]
(n = 196)
107.3 ± 37.7
[2.8 ± 1.0]
(n = 235)
0.04
Total cholesterol, mg/dL
[mmol/L]
182.7 ± 45.4
[4.7 ± 1.2]
(n = 472)
179.7 ± 45.5
[4.66 ± 1.2]
(n = 205)
183.4 ± 43.5
[4.8 ± 1.1]
(n = 241)
0.4
Plasma triglycerides, mg/dL
[mmol/L]
175.8 ± 121.1
[2.0 ± 1.4]
(n = 474)
212.1 ± 134.3
[2.4 ± 1.5]
(n = 208)
141.4 ± 94.9
[1.6 ± 1.1]
(n = 239)
<0.0001
Abbreviations: BMI = body mass index; BP = blood pressure; HDL = high-density lipoprotein; LDL = low-density lipoprotein; MetS = metabolic syndrome.
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Page 4 of 11MetS component responses to TRT by metabolic syndrome
status and TT level
TT significantly increased from baseline values in both
MetS+ and MetS- patients at all time points during
TRT (Table 3); however, free testosterone did not signif-
icantly change from baseline in MetS- patients after 6
and 12 months TRT and SHBG levels did not change in
either cohort at any time point. Neither mean TT levels
nor changes in TT levels from baseline were signifi-
cantly different between MetS+ and MetS- patients after
3, 6, and 12 months of TRT (Table 3).
Despite achieving similar TT levels after TRT, treatment
had different effects on MetS components in MetS+ and
MetS- patients (Figure 3). Statistically significant
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Table 2 Baseline Pearson correlation coefficients after adjusting for age
Total Testosterone Free Testosterone Bioavailable Testosterone SHBG
Pearson r, p-Value (n)
Waist circumference -0.20, <0.0001
(525)
0.01, 0.8
(340)
-0.14, 0.3
(55)
-0.10, 0.3
(102)
Hip circumference -0.15, 0.0005
(527)
0.02, 0.7
(341)
-0.19, 0.2
(55)
-0.10, 0.3
(102)
Weight -0.19, <0.0001
(531)
0.04, 0.4
(344)
-0.02, 0.9
(56)
-0.17, 0.09
(104)
BMI -0.22, <0.0001
(531)
0.04, 0.4
(344)
-0.14, 0.3
(56)
-0.18, 0.07
(104)
SBP -0.12, 0.005
(528)
0.04, 0.5
(341)
-0.15, 0.3
(56)
0.05, 0.6
(104)
DBP -0.20, <0.0001
(529)
-0.11, 0.04
(342)
-0.08, 0.6
(56)
0.0003, 1.0
(103)
Abbreviations: BMI = body mass index; DBP = diastolic blood pressure; SBP = systolic blood pressure; SHBG = sex hormone-binding globulin.
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cose, and blood pressure were found in MetS+ patients
after 12 months of TRT. MetS- patients did not show
improvement in any metabolic syndrome criteria at any
time point. It is unclear if these outcomes were related to
TRT dose since patients could be titrated up or down dur-
ing treatment as determined by the physician to achieve
steady TT levels.
Because we found that patients in the lowest TT quartile
at baseline were at an increased risk for metabolic syn-
drome classification, we examined if changes in MetS
components after TRT were different for patients in the
different quartiles. We found that TT levels significantly
increased from baseline at all time points in patients in the
lowest three quartiles (Quartiles 1-3), but not in the high-
est quartile (Quartile 4). The difference among the groups
in change from baseline was significant (Table 4). How-
ever, the mean TT levels achieved at months 3, 6, and 12
of TRT were not significantly different among the groups;
thus, the quartiles differed in change in TT, but not in
mean TT levels, during TRT. In contrast, SHBG levels did
not significantly change from baseline in any quartile at
any time point. However, the difference between mean
SHBG levels among the quartiles after 12 months of TRT
was significant (p = 0.002). Lastly, significant changes in
free testosterone were variable across quartiles and over
time within quartiles; unlike TT, the quartiles did not sig-
nificantly differ from each other in mean free testosterone
levels, nor in change from baseline.
For each TT quartile, we examined changes in metabolic
syndrome components after 12 months of TRT (Table 5).
The only significant changes, found in Quartile 1 (<206
ng/dL [<7.1 nmol/L]), were for a mean loss of 2.1 cm [0.84
inches] in waist circumference (p = 0.002) and a drop of
11.5 mg/dL (0.64 mmol/L) in fasting glucose levels (p =
0.01). Nevertheless, there was no significant difference
between the quartiles in metabolic syndrome components.
Correlations of TT with MetS components after TRT
In the entire patient population, we examined the corre-
lations of final TT levels with MetS components and
related measures. At 12 months, laboratory values and
anthropometrics were measured in 214 of 218 returning
patients and TT levels were measured in 117 of these
patients. At this final time point, TT levels significantly
and inversely correlated with anthropometric measures
and glucose levels, even after partialing out the effects of
age: waist circumference (r = -0.37, p < 0.001, n = 115),
body mass index (BMI) (r = -0.34, p < 0.001, n = 115),
weight (r = -0.28, p = 0.003, n = 113), hip circumference
(r = -0.31, p < 0.001, n = 115) and fasting blood glucose
(r = -0.26, p = 0.03, n = 74). TT levels did not correlate
with systolic or diastolic BP, HDL cholesterol, or plasma
triglycerides.
In addition, the change in TT levels over 12 months
TRT significantly and inversely correlated with the
changes in weight (r = -0.23, p = 0.02, n = 109) and BMI
(r = -0.23, p = 0.02, n = 109), but not with fasting blood
glucose levels (r = -0.22, p = 0.06, n = 73). Changes in TT
did not correlate with changes in waist circumference, sys-
tolic blood pressure, or SHBG levels.
Discussion
Studies have observed a relationship between low testos-
terone and the components of metabolic syndrome [21],
which would suggest that a hypogonadal population
would have an increased prevalence of MetS. However, in
Table 3 TT, FT, and SHBG change from baseline after 3, 6, and 12 months of TRT
MetS+ MetS- p-Value, Differences
MetS+ vs MetS-
Mean Value, Mean Change from Baseline
(p-Value for Change from Baseline)
Mean Value Mean Change From Baseline
TT, ng/dL [nmol/L]
3 Months 505 [17.5], +223 (<0.0001) 503 [17.5], +197 (<0.0001) 0.9 0.7
6 Months 398 [13.8], +172 (<0.0001) 455 [15.8], +123 (0.0002) 0.09 0.3
12 Months 487, +261 (<0.0001) 512, +190 (<0.0001) 0.5 0.2
FT, pg/mL [pmol/L]
3 Months 84.1 [291.8], +36.8 (0.02) 93.8 [325.5], +39.6 (0.003) 0.6 0.9
6 Months 77.4 [268.6], +55.8 (0.0001) 63.5 [220.3], +12.6 (0.2) 0.3 0.01
12 Months 77.5 [269.0], +49.7 (0.0007) 68.8 [238.7], +15.0 (0.2) 0.5 0.05
SHBG, nmol/L
3 Months 24.6, +1.67 (0.7) 31.7, -0.06 (1.0) 0.1 0.7
6 Months 24.3, -1.37 (0.7) 31.2, -1.64 (0.6) 0.1 1.0
12 Months 17.7, -6.93 (0.1) 33.4, -0.80 (0.8) 0.005 0.3
Abbreviations: FT = free testosterone; SHBG = sex hormone-binding globulin; TT = total testosterone.
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Page 6 of 11the TRiUS population of hypogonadal men, 37% of the
evaluated patients met the criteria for metabolic syndrome
at baseline, which is consistent with the prevalence of
metabolic syndrome in US adult men (34.8%-41.9%) [22].
We did find that low TT levels (<206 ng/dL [<7.1 nmol/
L]) increased the risk of being classified as MetS+ and that
TT levels significantly correlated with some MetS compo-
nents before and after TRT. We found that TRT signifi-
cantly increased testosterone levels in both MetS+ and
MetS- hypogonadal populations and both achieved similar
TT levels. Changes in MetS components, however, were
only seen in MetS+ patients, including decreased fasting
blood glucose levels, waist circumference, and BP.
Although these changes were significant, no MetS+
patients changed MetS status. Given the patients’ high
baseline measurements, the need to have improvement
across 1-3 components concurrently to change status, and
the fact that the mean improvements did not break
through the lower thresholds for MetS criteria, this may
not be surprising.
In the literature, there is robust evidence of an associa-
tion between metabolic conditions and low testosterone
and/or SHBG [21,23-26]. Low testosterone levels are
associated with, and predictive of, weight gain [27], cen-
tral obesity [8,28], hypertension [29], MetS [8], insulin
resistance [30], and type 2 diabetes [9,24,30,31]. Low tes-
tosterone is found in 33% of type 2 diabetes patients,
including those younger than 35 years, as compared to
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Figure 3 Change from baseline in MetS components. Change from baseline (mean ± SE) in waist circumference (A), fasting blood glucose
(B), systolic BP (C), diastolic BP (D), HDL cholesterol (E), and plasma triglycerides (F) in patients with metabolic syndrome (gray) and without
metabolic syndrome (black) at 3, 6, and 12 months on TRT. *p ≤ 0.005, **p ≤ 0.05. Abbreviations: BP = blood pressure; HDL = high-density
lipoprotein; MetS = metabolic syndrome; TRT = testosterone replacement therapy.
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Page 7 of 11only 6% in men with type 1 diabetes [26]. In prostate can-
cer patients who undergo chemical castration therapy,
testosterone levels are suddenly and drastically reduced,
resulting in increased fat deposition, increased insulin
levels, impaired insulin sensitivity, and increased risk of
diabetes and MetS classification [32,33]. The evidence for
the association between hypogonadism and diabetes is
strong enough to warrant its inclusion in the most cur-
rent treatment guidelines for hypogonadism [2], which
recommend screening for low testosterone in patients
Table 4 TT, FT, and SHBG change from baseline after 3, 6, and 12 months of TRT, by baseline testosterone level
quartiles
Quartile 1
(<206 ng/dL)
[<7.1 nmol/L]
Quartile 2
(206-256 ng/dL)
[7.1-8.9 nmol/L]
Quartile 3
(257-330 ng/dL)
[8.9-11.5 nmol/L]
Quartile 4
(≥331 ng/dL)
[≥11.5 nmol/L]
p-Value, Differences Among Quartiles
Mean Value, Mean Change from Baseline
(p-Value for Change from Baseline)
Mean Value Mean Change From Baseline
TT, ng/dL [nmol/L]
3 Months 465 [16.1], +307
(<0.0001)
466 [16.2], +234
(<0.0001)
543 [18.8], +248
(0.0002)
520 [18.0], +59
(0.3)
0.7 0.02
6 Months 405 [14.1], +244
(<0.0001)
379 [13.2], +148
(0.0007)
425 [14.7], +135
(0.01)
535 [18.6], -3.7
(0.9)
0.09 0.002
12 Months 519 [18.0], +359
(<0.0001)
456 [15.8], +225
(<0.0001)
496 [17.2], +206
(0.0003)
520 [18.0], +3.6
(0.9)
0.7 <0.0001
FT, pg/mL [pmol/L]
3 Months 74 [256.8], +32
(0.1)
93 [322.7], +19
(0.5)
121 [419.9], +80
(0.0002)
80 [277.6], +17
(0.03)
0.3 0.1
6 Months 84 [291.5], +57
(0.0007)
71 [246.4], +3.8
(0.8)
82 [284.5], +45
(0.02)
69 [239.4], +6.3
(0.7)
0.8 0.06
12 Months 87 [301.9], +59
(0.0008)
67 [232.5], +9.0
(0.7)
56 [194.3], +18
(0.3)
70 [242.9], +6.9
(0.7)
0.5 0.1
SHBG, nmol/L
3 Months 27.9, +2.83
(0.7)
24.1, +0.1
(1.0)
32.1, +1.52
(0.7)
37.2, -1.66
(0.7)
0.2 0.9
6 Months 25.6, -1.00
(0.9)
25.7, +3.30
(0.6)
26.5, -3.84
(0.4)
38.9, -1.49
(0.7)
0.06 0.8
12 Months 19.4, -6.50
(0.4)
20.7, -1.45
(0.8)
25.2, -6.72
(0.1)
45.8, +5.75
(0.3)
0.002 0.3
Abbreviations: FT = free testosterone; SHBG = sex hormone-binding globulin; TT = total testosterone.
Table 5 12-month changes from baseline in MetS components and cardiovascular values by baseline testosterone
level quartiles
Quartile 1
(<206 ng/dL)
[<7.1 nmol/L]
Quartile 2
(206-256 ng/dL)
[7.1-8.9 nmol/L]
Quartile 3
(257-330 ng/dL)
[8.9-11.5 nmol/L]
Quartile 4
(≥331 ng/dL)
[≥11.5 nmol/L]
Differences Among Quartiles
Mean Change from Baseline
(p-Value)
p-Value
Waist circumference,
cm [inches]
-2.1 [-0.84]
(0.002)
-1.2 [-0.49]
(0.1)
+0.5 [+0.20]
(0.5)
-0.1 [-0.03]
(0.9)
0.06
FBG,
mg/dL [mmol/L]
-11.5 [-0.64]
(0.01)
+0.76 [+0.04]
(0.9)
-7.7 [-0.43]
(0.1)
+1.1 [+0.06]
(0.8)
0.2
Systolic BP,
mmHg
-1.5
(0.4)
-1.0
(0.6)
-2.9
(0.2)
+1.9
(0.4)
0.4
Diastolic BP, mmHg -1.5
(0.2)
-2.3
(0.07)
-2.5
(0.09)
+0.3
(0.8)
0.4
HDL cholesterol, mg/dL [mmol/L] -0.45 [-0.01]
(0.8)
-2.1 [-0.05]
(0.3)
-0.89 [-0.02]
(0.6)
+0.54 [+0.01]
(0.8)
0.8
Plasma TG, mg/dL [mmol/L] -17.8 [-0.20]
(0.3)
-11.4 [-0.12]
(0.6)
-34.2 [-0.39]
(0.08)
+2.1 [+0.02]
(0.9)
0.7
BP = blood pressure; FBG = fasting blood glucose; HDL = high-density lipoprotein; MetS = metabolic syndrome; TG = triglycerides.
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Page 8 of 11with type 2 diabetes. Our findings that TT levels corre-
lated with waist circumference and fasting blood glucose
in a hypogonadal population are in line with these
observations.
However, it is unclear to what extent TRT can improve
metabolic symptoms in hypogonadal men. Studies of
TRT in hypogonadal men have shown improvements in
body composition (fat-to-lean mass ratio) [11] and insu-
lin sensitivity that can reliably be seen early in TRT (1-6
weeks) [34]. Changes in BMI are not always seen since a
loss of fat weight can be replaced by lean muscle weight
after TRT [35]. Recently, in a hypogonadal male popula-
tion with type 2 diabetes and/or metabolic syndrome,
Jones and colleagues [17] showed a 15.2% reduction in
HOMA-IR (homeostasis model of assessment–insulin
resistance) compared to placebo after 6 months of TRT
use. This was maintained through the 12 months of the
study. We found that TRT resulted in lowered waist cir-
cumference (visceral fat) and fasting blood glucose, but
only in patients with very low testosterone levels (<206
ng/dL [<7.1 nmol/L]) or in MetS+ patients. We saw
neither improvement, nor worsening, in lipid parameters
in either MetS+ or MetS- cohorts; this reflects the results
reported in a review by Jones [34], which found that the
effect of TRT on HDL cholesterol is reduction in 25% of
the studies, increase in 25% of the studies, and no effect
in 50% of the studies.
In the MetS+ population of our study, improvements
were generally seen at later time points: at 12 months for
waist circumference and fasting blood glucose levels, and
at 6 months for BP. This generally agrees with the litera-
ture, and it is possible that metabolic benefits of TRT
may not be seen until later time points. At 3 months
TRT, placebo-controlled studies in men with type 2 dia-
betes demonstrated mixed results; there were significant
reductions in waist circumference but not BMI [13],
reductions in waist circumference and fasting blood glu-
cose, but not BP [12], and reductions in body weight and
blood glucose [36]. In a longer, 8-month placebo-con-
trolled trial of TRT in hypogonadal obese men, improve-
ments over placebo were seen in visceral (abdominal) fat
mass, blood glucose, diastolic BP, and serum cholesterol,
but not BMI [37]. In a 12-month study of hypogonadal
men with MetS, improvements were seen at 6 months in
insulin sensitivity, waist circumference, and fat mass, and
further improvements were seen at 12 months [15]. In a
2-year study by Haider et al of hypogonadal men treated
with parenteral testosterone undecanoate, BMI, waist
size, and weight continued to decrease over the full 24
months, while improvements in fasting glucose and lipid
levels were seen only during the first 12 months [38]. It
should be noted that in this study, 77% (37/47) of men
with MetS no longer met the criteria for the condition
after receiving TRT for 2 years [38].
In addition to prolonged use, metabolic benefit has also
been seen when TRT is used in combination with weight
loss. Heufelder et al conducted a 12-month, placebo con-
trolled study of diet and exercise with or without TRT in
32 hypogonadal men with MetS and newly diagnosed type
2 diabetes [14]. They found that while there were improve-
ments in all MetS components in both groups, addition of
TRT to diet and exercise significantly improved glycemic
control and waist circumference over diet and exercise
alone. Using the ATP III definition of MetS as we did in
the current study, they found that 81.3% of the TRT+diet
+exercise group and 31.3% of the diet+exercise group no
longer met the criteria for MetS after 12 months in the
study. Our patient registry showed that TRT alone in
MetS+ patients can improve two of the five criteria for
MetS (ie, decreased fasting blood glucose levels and waist
circumference). This result may be more realistic in clini-
cal practice since many patients struggle with diet and
exercise regimens outside of a structured clinical study.
Heufelder et al also found a small improvement in TT
levels with diet and exercise alone, emphasizing the bidir-
ectional link between testosterone and MetS criteria.
Because we did not record changes in diet and exercise in
our study, it is unknown if improved MetS criteria had
any impact on testosterone levels in our study.
Importantly for prediabetic men, we found that TRT
improved fasting glucose levels in MetS+ men. This rela-
tionship between testosterone and insulin was high-
lighted in Yialamas et al [32], who found decreased
insulin sensitivity and increased fasting blood glucose
levels after withdrawal of TRT in young, healthy men
with idiopathic hypogonadotropic hypogonadism. Similar
results have been reported by Pitteloud et al [39,40],
though Rabiee et al [41] found no change in insulin sen-
sitivity in response to serum testosterone suppression in
healthy non-hypogonadal men. Thus, insulin sensitivity
may be related to a chronic hypogonadal state, though
the mechanism for this is currently unclear.
An important limitation of our study was the lack of
data regarding concomitant medication use for diabetes,
dyslipidemia, or hypertension; because the registry was
not designed specifically to evaluate metabolic syndrome,
this information was not systematically collected. With-
out consistent documentation of the use of these conco-
mitant medications, it is not possible to accurately
determine the extent to which the effects on metabolic
parameters reflect effects of TRT, or an optimization of
medications these patients may be using. Other limita-
tions of our study were typical of an observational study
or patient registry. Patient behavior and physician proto-
col and practice were not defined by the registry proto-
col. Thus, we observed a high degree of variability due to
inconsistency in patient follow-up visits, hypogonadism
d e f i n e da tt h ep h y s i c i a n ’s discretion, no testosterone
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Page 9 of 11washout period before enrollment, no placebo control,
and no centralized laboratory testing facility. This last
limitation may have contributed to the inconsistent
change we observed in free testosterone after TRT; it is
unclear why free testosterone did not correlate with TT,
although it should be noted that a uniform method of
free testosterone assessment was not stipulated in the
registry (ie, calculated vs measured; analog assay vs mass
spectrometry). Because our data reflect the natural beha-
vior of patients and physicians, the findings can be gener-
alized to patients seeking medical attention for
hypogonadal symptoms and those being treated for
hypogonadism.
Conclusions
Our findings are consistent with the literature showing an
association between TT levels and MetS and the positive
influence of TRT on waist circumference and fasting
blood glucose levels. Furthermore, we show that 6 to 12
months of TRT may be required for more benefit in the
typical hypogonadal patient with MetS. Numerous small
studies have provided qualitative evidence that TRT pro-
vides metabolic benefit. In addition to the recently pub-
lished results from the TIMES2 study [17], there is a need
for large, long-term, placebo-controlled trials confirming
the important observed benefits of TRT in hypogonadal
men with MetS. In clinical practice, testing for low testos-
terone may be warranted in men with MetS who also
exhibit other signs or symptoms of testosterone deficiency.
Prior presentation/publication
Data from this paper were presented at the Endocrine
Society 2010 Annual Meeting (June 19-22, 2010, San
Diego, California) and published in abstract form as Bhat-
tacharya RK, et al. Endocrine Reviews. 2010;31(3 suppl 1):
S466. Abstract P1-399. A companion paper describing the
methodology and baseline symptoms and comorbidities of
participants in the TRiUS registry has been published:
Miner MM, Khera M, Bhattacharya R, Blick G, Kushner
H. Baseline data from the TRiUS registry: symptoms and
comorbidities of testosterone deficiency. Postgrad Med.
2011;123:17-27.
Acknowledgements and Funding
Funding to support this study and the preparation of this manuscript was
provided by Auxilium Pharmaceuticals. The authors thank Tara Gupta, PhD
of MedVal Scientific Information Services, LLC for providing medical writing
and editorial assistance. This manuscript was prepared according to the
International Society for Medical Publication Professionals’“ Good Publication
Practice for Communicating Company-Sponsored Medical Research: The
GPP2 Guidelines.”
Author details
1University of Kansas Medical Center, 3901 Rainbow Blvd, MS2024, Kansas
City, KS 66160, USA.
2Scott Department of Urology, Baylor College of
Medicine, 6620 Main Street, Suite 1325, Houston, TX 77030, USA.
3Circle
Medical LLC, 153 East Avenue, Suite 32, Norwalk, CT 06851, USA.
4Auxilium
Pharmaceuticals, 40 Valley Stream Parkway, Malvern, PA 19355, USA.
5Miriam
Hospital Men’s Health Center, 164 Summit Avenue, Providence, RI 02906,
USA.
Authors’ contributions
All authors contributed equally and each were involved in study design,
data acquisition, or data analysis/interpretation and in drafting or critically
revising the manuscript. All authors reviewed the final manuscript and gave
approval for publication.
Competing interests
RKB - Amgen: speaker; Auxilium: consultant, steering committee; Bristol-
Myers Squibb: speaker; Novartis: speaker; Solvay: speaker. MK - Allergan:
research funding; Auxilium: speaker; Boehringer Ingelheim: speaker; Slate:
speaker. GB - Auxilium: investigator, speaker; Tibotec: advisor/consultant,
speaker; ViiV: advisor/consultant, speaker; Virxsys: research funding, advisor/
consultant. HK - Auxilium: employee. DN - Auxilium: employee. MMM -
Auxilium: research funding; advisor; GlaxoSmithKline: research funding; Endo:
advisor.
Received: 22 July 2011 Accepted: 1 November 2011
Published: 1 November 2011
References
1. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C: Prevalence of
hypogonadism in males aged at least 45 years: the HIM study. Int J Clin
Pract 2006, 60(7):762-769.
2. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ,
Swerdloff RS, Montori VM: Testosterone therapy in men with androgen
deficiency syndromes: an Endocrine Society clinical practice guideline. J
Clin Endocrinol Metab 2010, 95(6):2536-2559.
3. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR: Longitudinal
effects of aging on serum total and free testosterone levels in healthy
men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001,
86(2):724-731.
4. Guay AT: The emerging link between hypogonadism and metabolic
syndrome. J Andol 2009, 30(4):370-376.
5. National Cholesterol Education Program, National Institutes of Health: Third
Report of the National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation
2002, 106(25):3143-3421.
6. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA,
Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F: Diagnosis
and management of the metabolic syndrome. An American Heart
Association/National Heart, Lung, and Blood Institute Scientific
Statement. Circulation 2005, 112(17):2735-2752.
7. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA: Clinical
management of metabolic syndrome: report of the American Heart
Association/National Heart, Lung, and Blood Institute/American Diabetes
Association conference on scientific issues related to management.
Circulation 2004, 109(4):551-556.
8. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP,
Valkonen VP, Salonen R, Salonen JT: Testosterone and sex hormone-
binding globulin predict the metabolic syndrome and diabetes in
middle-aged men. Diabetes Care 2004, 27(5):1036-1041.
9. Ding EL, Song Y, Malik VS, Liu S: Sex differences of endogenous sex
hormones and risk of type 2 diabetes: a systematic review and meta-
analysis. JAMA 2006, 295(11):1288-1299.
10. Zitzmann M: Testosterone deficiency, insulin resistance and the
metabolic syndrome. Nat Rev Endocrinol 2009, 5(12):673-681.
11. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G,
Matsumoto AM, Weber T, Berman N: Transdermal testosterone gel
improves sexual function, mood, muscle strength, and body
composition parameters in hypogonadal men. J Clin Endocrinol Metab
2000, 85(8):2839-2853.
12. Kapoor D, Goodwin E, Channer KS, Jones TH: Testosterone replacement
therapy improves insulin resistance, glycaemic control, visceral adiposity
and hypercholesterolaemia in hypogonadal men with type 2 diabetes.
Eur J Endocrinol 2006, 154(6):899-906.
Bhattacharya et al. BMC Endocrine Disorders 2011, 11:18
http://www.biomedcentral.com/1472-6823/11/18
Page 10 of 1113. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH: The effect of
testosterone replacement therapy on adipocytokines and C-reactive
protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007,
156(5):595-602.
14. Heufelder AE, Saad F, Bunck MC, Gooren L: Fifty-two-week treatment with
diet and exercise plus transdermal testosterone reverses the metabolic
syndrome and improves glycemic control in men with newly diagnosed
type 2 diabetes and subnormal plasma testosterone. J Andol 2009,
30(6):726-733.
15. Aversa A, Bruzziches R, Francomano D, Spera G: Efficacy and safety of two
different testosterone undecanoate formulations in hypogonadal men
with metabolic syndrome. J Endocrinol Invest 2010, 33(11):776-783.
16. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A,
Spera G: Effects of testosterone undecanoate on cardiovascular risk
factors and atherosclerosis in middle-aged men with late-onset
hypogonadism and metabolic syndrome: results from a 24-month,
randomized, double-blind, placebo-controlled study. J Sex Med 2010,
7(10):3495-3503.
17. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM,
Volterrani M, Yellowlees A, Howell JD, Channer KS: Testosterone
replacement in hypogonadal men with type 2 diabetes and/or
metabolic syndrome (the TIMES2 study). Diabetes Care 2011, 34:828-837.
18. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F:
Effects of testosterone supplementation on markers of the metabolic
syndrome and inflammation in hypogonadal men with the metabolic
syndrome: the double-blind placebo-controlled Moscow study. Clin
Endocrinol (Oxf) 2010, 73(5):602-612.
19. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A,
Forti G, Mannucci E, Maggi M: Testosterone and metabolic syndrome: a
meta-analysis study. J Sex Med 2011, 8(1):272-283.
20. Miner MM, Khera M, Bhattacharya R, Blick G, Kushner H: Baseline data from
the TRiUS registry: symptoms and comorbidities of testosterone
deficiency. Postgrad Med 2011, 123(3):17-27.
21. Traish AM, Guay A, Feeley R, Saad F: The dark side of testosterone
deficiency: I. Metabolic syndrome and erectile dysfunction. J Andol 2009,
30(1):10-22.
22. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA,
Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic
syndrome: a joint interim statement of the International Diabetes
Federation Task Force on Epidemiology and Prevention; National Heart,
Lung, and Blood Institute; American Heart Association; World Heart
Federation; International Atherosclerosis Society; and International
Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
23. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT:
Endogenous sex hormones and metabolic syndrome in aging men. J
Clin Endocrinol Metab 2005, 90(5):2618-2623.
24. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB: Low
sex hormone-binding globulin, total testosterone, and symptomatic
androgen deficiency are associated with development of the metabolic
syndrome in nonobese men. J Clin Endocrinol Metab 2006, 91(3):843-850.
25. Traish AM, Saad F, Guay A: The dark side of testosterone deficiency: II.
Type 2 diabetes and insulin resistance. J Andol 2009, 30(1):23-32.
26. Dandona P, Dhindsa S, Chandel A, Chaudhuri A: Hypogonadotropic
hypogonadism in men with type 2 diabetes. Postgrad Med 2009,
121(3):45-51.
27. Saad F, Gooren LJ: The role of testosterone in the etiology and treatment
of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes
2011, 2011:471584.
28. Svartberg J, von Muhlen D, Sundsfjord J, Jorde R: Waist circumference and
testosterone levels in community dwelling men. The Tromso study. Eur J
Epidemiol 2004, 19(7):657-663.
29. Rosmond R, Wallerius S, Wanger P, Martin L, Holm G, Bjorntorp P: A 5-year
follow-up study of disease incidence in men with an abnormal hormone
pattern. J Intern Med 2003, 254(4):386-390.
30. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB: Testosterone,
sex hormone-binding globulin, and the development of type 2 diabetes
in middle-aged men: prospective results from the Massachusetts male
aging study. Diabetes Care 2000, 23(4):490-494.
31. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, Dobs A,
Basaria S, Golden SH, Platz EA: Androgens and diabetes in men: results
from the Third National Health and Nutrition Examination Survey
(NHANES III). Diabetes Care 2007, 30(2):234-238.
32. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ: Acute sex
steroid withdrawal reduces insulin sensitivity in healthy men with
idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab
2007, 92(11):4254-4259.
33. Basaria S: Androgen deprivation therapy, insulin resistance, and
cardiovascular mortality: an inconvenient truth. J Andol 2008,
29(5):534-539.
34. Jones TH: Effects of testosterone on type 2 diabetes and components of
the metabolic syndrome. J Diabetes 2010, 2(3):146-156.
35. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R:
Testosterone treatment in elderly men with subnormal testosterone
levels improves body composition and BMD in the hip. Int J Impot Res
2008, 20(4):378-387.
36. Boyanov MA, Boneva Z, Christov VG: Testosterone supplementation in
men with type 2 diabetes, visceral obesity and partial androgen
deficiency. Aging Male 2003, 6(1):1-7.
37. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G,
Bjorntorp P: The effects of testosterone treatment on body composition
and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord
1992, 16(12):991-997.
38. Haider A, Gooren LJ, Padungtod P, Saad F: Beneficial effects of 2 years of
administration of parenteral testosterone undecanoate on the metabolic
syndrome and on non-alcoholic liver steatosis and C-reactive protein.
Horm Molec Biol Clin Invest 2010, 1(1):27-33.
39. Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ:
Increasing insulin resistance is associated with a decrease in Leydig cell
testosterone secretion in men. J Clin Endocrinol Metab 2005,
90(5):2636-2641.
40. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF,
Tripathy D, Yialamas M, Groop L, Elahi D, Hayes FJ: Relationship between
testosterone levels, insulin sensitivity, and mitochondrial function in
men. Diabetes Care 2005, 28(7):1636-1642.
41. Rabiee A, Dwyer AA, Caronia LM, Hayes FJ, Yialamas MA, Andersen DK,
Thomas B, Torriani M, Elahi D: Impact of acute biochemical castration on
insulin sensitivity in healthy adult men. Endocr Res 2010, 35(2):71-84.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6823/11/18/prepub
doi:10.1186/1472-6823-11-18
Cite this article as: Bhattacharya et al.: Effect of 12 months of
testosterone replacement therapy on metabolic syndrome components
in hypogonadal men: data from the Testim Registry in the US (TRiUS).
BMC Endocrine Disorders 2011 11:18.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bhattacharya et al. BMC Endocrine Disorders 2011, 11:18
http://www.biomedcentral.com/1472-6823/11/18
Page 11 of 11